CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi

The main market opportunities for CD38-targeted immunotherapies lie in multiple myeloma treatment, given its high CD38 expression. With successful therapeutics like daratumumab and isatuximab, ...
Mirage News

Serum Markers' Role in Breast Cancer Diagnosis & Treatment

Breast cancer remains a predominant global health challenge for women, with late-stage diagnosis being a key contributor to its high mortality. This ...
News-Medical.Net on MSN

Missing cancer gene may boost response to immunotherapy

A recently approved group of drugs - immune checkpoint inhibitors - can boost the body's ability to eliminate a tumor and ...
Le Lézard

Intratumoral Cancer Therapies Market to Reach USD 630.7 Million by 2033 as Next-Generation Localized Immunotherapies Transform Solid Tumor Treatment

According to DataM Intelligence, the Intratumoral Cancer Therapies Market Size increased from USD 219.79 million in 2023 to USD 246.4 million in 2024, and is expected to climb to USD 630.7 million by ...
Le Lézard

In-Silico Clinical Trials Market Set to Reach USD 6.39 Billion by 2033 as Pharma and MedTech Accelerate Digital-First Validation, AI Modeling & Virtual Patient Simulations

According to DataM Intelligence, the In-Silico Clinical Trials Market Size was USD 3.76 billion in 2023, increased to USD 3.95 billion in 2024, and is projected to achieve USD 6.39 billion by 2033, ...